Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CLLS

Cellectis ADR

Nov 10 • 04:00PM ET

3.55

+0.36 11.29 %

Healthcare • Biotechnology • France • NASD

Peers: CRSP NTLA SGMO BLUE EDIT QURE RCKT CYTK ADAP ARCT

Index	-	P/E	-	EPS (ttm)	-0.33	Insider Own	14.28%	Shs Outstand	100.33M	Perf Week	8.56%
Market Cap	255.92M	Forward P/E	-	EPS next Y	-0.81	Insider Trans	0.00%	Shs Float	61.80M	Perf Month	-12.13%
Enterprise Value	182.92M	PEG	-	EPS next Q	-0.31	Inst Own	16.36%	Short Float	0.44%	Perf Quarter	33.46%
Income	-35.71M	P/S	3.40	EPS this Y	-111.36%	Inst Trans	-3.92%	Short Ratio	2.16	Perf Half Y	135.10%
Sales	75.24M	P/B	3.54	EPS next Y	7.06%	ROA	-9.67%	Short Interest	0.27M	Perf YTD	97.22%
Book/sh	1.00	P/C	1.33	EPS next 5Y	-	ROE	-31.07%	52W High	5.48 -35.21%	Perf Year	100.56%
Cash/sh	2.67	P/FCF	-	EPS past 3/5Y	45.79% 29.97%	ROIC	-18.49%	52W Low	1.10 222.73%	Perf 3Y	45.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	10.99% 22.23%	Gross Margin	72.37%	Volatility	5.49% 8.12%	Perf 5Y	-77.66%
Dividend TTM	-	EV/Sales	2.43	EPS Y/Y TTM	-	Oper. Margin	-46.10%	ATR (14)	0.30	Perf 10Y	-88.67%
Dividend Ex-Date	-	Quick Ratio	1.49	Sales Y/Y TTM	158.54%	Profit Margin	-47.46%	RSI (14)	51.59	Recom	1.75
Dividend Gr. 3/5Y	- -	Current Ratio	1.49	EPS Q/Q	102.51%	SMA20	-1.93%	Beta	2.86	Target Price	7.22
Payout	-	Debt/Eq	1.19	Sales Q/Q	115.53%	SMA50	3.97%	Rel Volume	1.53	Prev Close	3.19
Employees	222	LT Debt/Eq	0.92	Earnings	Nov 07 AMC	SMA200	66.92%	Avg Volume	126.43K	Price	3.55
IPO	Mar 25, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	104.32% 289.13%	Trades		Volume	192,979	Change	11.29%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-17-23	Initiated	Bryan Garnier	Buy	$6
May-18-22	Upgrade	Robert W. Baird	Neutral → Outperform	$10
Jan-06-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$39 → $16
Nov-30-21	Initiated	JMP Securities	Mkt Outperform	$20
Nov-08-21	Downgrade	William Blair	Outperform → Mkt Perform
Oct-08-21	Downgrade	Robert W. Baird	Outperform → Neutral	$39 → $10
Apr-28-21	Downgrade	Guggenheim	Buy → Neutral
Mar-16-21	Upgrade	Robert W. Baird	Neutral → Outperform	$23 → $39
Aug-19-20	Upgrade	Citigroup	Neutral → Buy	$15 → $32
May-12-20	Initiated	Robert W. Baird	Outperform	$20
Mar-06-20	Downgrade	Goldman	Neutral → Sell	$15 → $11
Oct-30-19	Resumed	Guggenheim	Buy	$28
Aug-09-19	Initiated	BTIG Research	Buy	$37
May-24-19	Resumed	Citigroup	Neutral	$22
Mar-14-19	Initiated	William Blair	Outperform
Dec-19-18	Initiated	Goldman	Neutral
Jul-16-18	Initiated	Barclays	Overweight	$50
Mar-16-18	Initiated	Guggenheim	Neutral
Sep-05-17	Reiterated	Wells Fargo	Outperform	$33 → $40
Sep-05-17	Downgrade	SunTrust	Buy → Hold

Show Previous Ratings

Nov-07-25 04:30PM	Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +11.29%
11:30AM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-03-25 09:15AM	Cellectis to Present a Development Update for eti-cel at ASH 2025 (GlobeNewswire) -5.22%
Oct-31-25 04:30PM	Cellectis to Report Third Quarter Financial Results on November 7, 2025 (GlobeNewswire)
Oct-16-25 03:19PM	Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL (GlobeNewswire) +9.98%
07:00AM	Loading…
07:00AM	Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers (GlobeNewswire)
Oct-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +8.22% +12.57%
02:40AM	Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress (GlobeNewswire)
Sep-03-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Aug-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Aug-04-25 04:30PM	Cellectis Reports Second Quarter 2025 Financial Results & Business Updates (GlobeNewswire) -16.23%
10:04AM	Earnings To Watch: Cellectis SA (CLLS) Reports Q2 2025 Result (GuruFocus.com)
Jul-28-25 04:30PM	Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025 (GlobeNewswire) +13.10%
Jul-04-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jun-26-25 04:30PM	Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025 (GlobeNewswire)
04:30PM	Loading…
Jun-05-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
May-21-25 04:30PM	Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025 (GlobeNewswire)
May-12-25 04:30PM	Cellectis Reports Financial Results for the First Quarter 2025 (GlobeNewswire) -6.62%
May-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
May-06-25 04:30PM	Cellectis to Report First Quarter Financial Results on May 12, 2025 (GlobeNewswire)
Apr-28-25 04:30PM	Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting (GlobeNewswire)
Apr-22-25 09:00AM	Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal (MarketBeat)
Apr-21-25 05:02PM	Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... (GuruFocus.com)
Apr-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +5.00%
Mar-13-25 06:07PM	Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update (GlobeNewswire)
Mar-07-25 04:30PM	Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 (GlobeNewswire)
Mar-06-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Feb-24-25 01:30AM	Cellectis Presents 'Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 (GlobeNewswire)
Feb-04-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jan-28-25 08:00AM	Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer (GlobeNewswire)
04:30PM	Loading…
Jan-08-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -8.10%
Jan-07-25 11:28AM	Do Options Traders Know Something About Cellectis (CLLS) Stock We Don't? (Zacks)
Dec-29-24 08:24AM	Analysts Predict 400% Upside Potential for This Penny Stock (GuruFocus.com)
Dec-10-24 04:30PM	Cellectis announces the drawdown of the third tranche of 5 million under the credit facility agreement entered with the European Investment Bank (EIB) (GlobeNewswire)
Dec-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-06-24 04:38PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-05-24 04:30PM	Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting (GlobeNewswire)
Nov-04-24 04:30PM	Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 (GlobeNewswire)
07:14AM	What To Expect From Cellectis SA (CLLS) Q3 2024 Earnings (GuruFocus.com)
Oct-30-24 04:30PM	Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 (GlobeNewswire)
Oct-23-24 06:29AM	Cellectis Presents New Gene-Editing Breakthroughs (TipRanks) +9.44%
Oct-22-24 02:00AM	Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress (GlobeNewswire)
Oct-02-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Sep-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Sep-03-24 04:30PM	Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety (GlobeNewswire) -5.83%
Aug-26-24 04:30PM	Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors (GlobeNewswire)
Aug-07-24 02:00AM	Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer (GlobeNewswire)
Aug-06-24 04:30PM	Cellectis Provides Financial Results for the Second Quarter 2024 (GlobeNewswire)
Aug-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Aug-02-24 09:53AM	Cellectis starts alemtuzumab revival with FDA orphan drug win in leukaemia (Pharmaceutical Technology)
Aug-01-24 04:30PM	FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment (GlobeNewswire)
Jul-25-24 04:30PM	FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment (GlobeNewswire) +12.20%
Jul-10-24 09:35AM	Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS) (Zacks)
Jul-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jun-28-24 04:30PM	Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 (GlobeNewswire)
Jun-20-24 04:30PM	Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing (GlobeNewswire)
Jun-18-24 12:00PM	Cellectis (CLLS) Upgraded to Buy: Here's Why (Zacks) -5.84%
09:35AM	After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS) (Zacks)
Jun-12-24 04:30PM	Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications (GlobeNewswire)
Jun-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +6.23%
Jun-04-24 04:30PM	Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia (GlobeNewswire)
May-29-24 04:30PM	Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024 (GlobeNewswire)
May-28-24 08:52PM	CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:30PM	Cellectis Reports Financial Results for First Quarter 2024 (GlobeNewswire)
May-27-24 04:30PM	Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024 (GlobeNewswire)
May-16-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
May-06-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +12.04% -7.46%
04:22AM	Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca (MT Newswires)
02:00AM	Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca (GlobeNewswire)
May-03-24 06:10AM	Cellectis CFO Bing Wang Retires, Interim CFO Appointed (MT Newswires)
May-02-24 04:30PM	Cellectis Appoints Arthur Stril as Interim Chief Financial Officer (GlobeNewswire) +17.90%
Apr-29-24 10:53PM	CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:46PM	Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 (GlobeNewswire)
Apr-22-24 04:30PM	Cellectis Presents Novel TALEN Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs (GlobeNewswire)
Apr-10-24 04:30PM	Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs (GlobeNewswire)
Apr-08-24 04:30PM	Cellectis Announces Two Poster Presentations on Novel TALEN Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting (GlobeNewswire)
Apr-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Mar-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Feb-02-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jan-16-24 04:30PM	Cellectis announces the drawdown of the second tranche of 15 million under the credit facility agreement entered with the European Investment Bank (EIB) (GlobeNewswire) -5.42%
Jan-08-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Dec-22-23 04:30PM	Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023 (GlobeNewswire)
Dec-01-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -5.59%
Nov-17-23 04:30PM	Cellectis' Shareholders Meeting to be Held on December 22, 2023 (GlobeNewswire) +11.83% +5.80%
Nov-15-23 02:30AM	Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca (GlobeNewswire) +9.38%
Nov-06-23 04:30PM	Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023 (GlobeNewswire) -13.41%
Nov-03-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-02-23 04:30PM	Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting (GlobeNewswire) +14.02%
Nov-01-23 04:30PM	Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire) +172.16%
08:13AM	Why Is Cellectis (CLLS) Stock Up 175% Today? (InvestorPlace)
08:02AM	AstraZeneca takes 22% stake in Cellectis as part of collab for 10 cell and gene therapies (FierceBiotech.com)
03:00AM	Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca (GlobeNewswire)
Oct-31-23 04:30PM	Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Oct-24-23 04:30PM	Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress (GlobeNewswire) -12.50%
Oct-12-23 04:30PM	Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Syndrome Type 1 (APDS1) (GlobeNewswire)
Oct-03-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -7.79%
09:55AM	These 2 Strong Buy Penny Stocks Could Gain Over 500%, Says Baird (TipRanks)
Sep-27-23 04:30PM	Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Sep-05-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -8.96%
Aug-07-23 04:30PM	Cellectis Provides Full Report for Second Quarter 2023 Financial Results (GlobeNewswire)

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and Andre Choulika on February 20, 1999 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLLS

Cellectis ADR

Upgrade your FINVIZ experience